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Abstract
Background: Restless legs syndrome (RLS) is a neurological disorder with a lifetime prevalence of 3-10%. in
European studies. However, the diagnosis of RLS in primary care remains low and mistreatment is common.
Methods: The current article reports on the considerations of RLS diagnosis and management that were made
during a European Restless Legs Syndrome Study Group (EURLSSG)-sponsored task force consisting of experts and
primary care practioners. The task force sought to develop a better understanding of barriers to diagnosis in
primary care practice and overcome these barriers with diagnostic and treatment algorithms.
Results: The barriers to diagnosis identified by the task force include the presentation of symptoms, the language
used to describe them, the actual term “restless legs syndrome” and difficulties in the differential diagnosis of RLS.
Conclusion: The EURLSSG task force reached a consensus and agreed on the diagnostic and treatment algorithms
published here.
Background
Restless legs syndrome (RLS) is a neurological disorder
characterised by an irresistible urge to move the legs
especially at rest. Symptoms worsen in the evening and
night and improve with activity such as walking. RLS
may be secondary to, or exacerbated by, a number of
conditions that include iron deficiency, pregnancy, end-
stage renal disease (ESRD), diabetes and rheumatoid
arthritis, or with neurological disorders such as periph-
eral neuropathy.
As a consequence of sleep disruption and the inability
to remain still (including during the daytime, the symp-
toms of RLS can severely impact on activities of daily
living [1].
The main consequences of severe RLS are:
a. Sleep disruption: RLS is the sleep disorder which
causes the greatest chronic loss of sleep. Results
from several surveys report that most RLS patients
slept an average of 5 hours a day [2-5]. Sleep loss by
itself causes daytime drowsiness, difficulties concen-
trating, loss of performance and negatively impacts
mood.
b. Difficulties resting and remaining still: this hap-
pens predominantly in the evening and at night, but
also at other times during the day. Consequently
patients have difficulties with work, travelling and
social events [1].
Until recently RLS was considered a rare disorder;
poor recognition of symptoms, the absence of symptoms
during most of the day (with an onset only at night),
accompanied with an often “bizarre” description of
symptoms, frequently led to the consideration of a psy-
chogenic origin of these symptoms. The absence of any
classical objective findings on classical neurological
tests–such as nerve conduction studies or electromyo-
graphy–further contributed to this consideration.
Furthermore, whenever RLS patients experience sleep
disturbance, they frequently cannot relate their sleep
problem to the disturbance of their legs and do not
report these symptoms to their physician. As a result, a
lack of interest in RLS by the entire medical profession
* Correspondence: dgb.eurlssg@gmail.com
1Sleep Research Institute, Madrid, Spain
Full list of author information is available at the end of the article
Garcia-Borreguero et al. BMC Neurology 2011, 11:28
http://www.biomedcentral.com/1471-2377/11/28
© 2011 Garcia-Borreguero et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.has existed historically. Nevertheless, over the last dec-
ades, RLS has emerged not only as a common, but also
as a sometimes severe disorder [6]. In 1995 the Interna-
tional RLS Study Group (IRLSSG) established four clini-
c a ld i a g n o s t i cc r i t e r i af o rR L St h a tw e r el a t e rr e f i n e d
and reviewed during a National Institutes of Health
(NIH) workshop in 2002 (see Table 1) [7]. As far as the
prevalence of RLS is concerned, adult population studies
have been carried out and the majority of those under-
taken in Western Europe and North America have
shown a prevalence ranging between 3 and 10%.
Methods
Given the high prevalence of RLS, the diagnosis of this
disorder should occur principally in the primary care
setting. Unfortunately this is not the case as identifica-
tion of RLS in primary care occurs with substantial diffi-
culties. Furthermore, RLS is mismanaged despite the
recent publication of evidence-based guidelines on its
treatment [8,9]. The published guidelines rarely address
the general practitioner (GP)/primary care physician
(PCP), instead they address for the most part neurolo-
gists and have tailored management and resources avail-
able to experts in neurology, psychiatry or sleep
medicine. There are few resources available to the GP
to facilitate RLS management. In order for RLS to be
appropriately managed from primary care upwards, it is
therefore necessary to provide GPs with both diagnostic
and treatment guidelines. A previous consensus based-
treatment algorithm was published by the Medical Advi-
sory Board of the Restless Legs Foundation in 2004 [10],
however, since this time many new randomized-con-
trolled studies have been published that change how
RLS should be treated.
In order to tackle emerging difficulties for diagnosing
RLS in primary care, the European RLS Study Group
http://www.eurlssg.org established a task force consist-
ing of experts and primary care practioners–authors of
the current paper–from several European countries with
the objective of identifying and overcoming barriers to
the diagnosis and treatment of RLS in primary care
during three consensus meetings that took place in sev-
eral European cities over 2008 and 2009. This report
summarises the discussions and conclusions of this task
force and proposes diagnostic and treatment algorithms
to facilitate the diagnosis and treatment of RLS in pri-
mary care.
Results
Barriers to diagnosis
Despite the high prevalence of RLS and the high percen-
tage of RLS sufferers with symptoms that impact on
activities of daily living, RLS remains underdiagnosed
and also misdiagnosed–as skin irritation, arthritis, mal-
ingering, and venous disorders in adults, and as growing
pains or attention deficit hyperactivity disorder (ADHD)
in children–which consequently leads to many sufferers
having to wait several years before a correct diagnosis is
made, this is especially the case for patients who have
chronic RLS that began in childhood. In a German
population-based survey the overall prevalence of a
known doctor diagnosis of RLS was 2.3%, the ratio of
diagnosed to undiagnosed RLS was 1:3 [11]. In a French
study only 5.3% of RLS sufferers received a diagnosis of
RLS despite the fact that 53% of the sample had con-
sulted their doctor with RLS symptoms; 60% of RLS suf-
ferers had received a previous vascular diagnosis mainly
related to venous disease [12]. In the REST primary care
study performed in the USA and five European coun-
tries, 64.8% of sufferers reported consulting a physician
about their RLS symptoms, of these only 58% received
any diagnosis, while 12.9% were given a diagnosis of
RLS; the general practitioner reported that only 37.9%
of these RLS sufferers had consulted for RLS symptoms
[6]. Similar examples of underdiagnosis and mismanage-
ment have been provided by large studies performed in
the UK, USA and in Ireland [1,4,13].
The diagnosis of RLS
A clinical diagnosis of RLS can only be made if patients
complain of four key symptoms which constitute the
essential criteria defined by the IRLSSG (Table 1 and
Table 1 Essential diagnostic criteria
Essential criteria Supportive criteria Associated features
An urge to move the legs, usually accompanied/caused by
uncomfortable/unpleasant sensations in the legs.
Positive family history of RLS. Natural clinical course of the disorder.
Urge to move or unpleasant sensations begin or worsen during
periods of rest or inactivity.
Positive response to dopaminergic
drugs.
Sleep disorders are a frequent but unspecific
symptom of the RLS.
Urge to move or unpleasant sensations are partially/totally
relieved by movement, at least as long as the activity continues.
PLMW/PLMS as assessed with
polysomnography or leg activity
devices.
Medical evaluation/physical examination:
The neurological examination is usually
normal.
Urge to move or unpleasant sensations are worse in the
evening/night than during the day, or only occur in the
evening/night.
Probable causes for secondary RLS should
be excluded.
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RLS, however, the diagnostic certainty of these criteria
can be improved if supportive clinical criteria, such as a
positive levodopa response,[16] periodic limb move-
ments (PLMs),[17] or the presence of a positive family,
[7] are present (Table 1). The four essential criteria are:
1. Urge to move the legs or other body parts usually
accompanied or caused by unpleasant sensations
It is possible that the patient has an urge to move that is
not accompanied by uncomfortable sensations. These
sensations appear predominantly in the legs, but the
arms, trunk and face [18] can also be affected [19]. The
symptoms are often described as being located deep
inside the legs, and a sense of movement inside the leg
is also evoked. Because the symptoms are unlike usual
sensory experiences, patients have difficulties in describ-
ing them. In this way, a myriad of terms are used by
patients to describe their symptoms: creeping, crawling,
itching, burning, tugging, indescribable, aching, like an
electric current, restless, painful etc [7,20].
2. Urge to move or unpleasant sensations begin or worsen
during rest or inactivity
T h eu r g et om o v et h el e g sa n d / o rt h eu n c o m f o r t a b l e
sensations being with rest, be it sitting or lying down.
The physical immobility and decreased central system
activity that characterize rest are thought to be impli-
cated in the onset of symptoms [21].
3. Urge to move or unpleasant sensations are partially or
totally relieved by movement
Relief from RLS symptoms is seen with activation of the
motor system. Symptoms, which can be unilateral or
bilateral, may be totally or partially relieved by move-
ment such as walking or stretching but reappear shortly
after movement ceases. The more severe the RLS, the
more vigorous the movement needs to be. If no relief is
seen with movement it is important to ask patients if
during the early stages of their RLS, movement relieved
symptoms; it is possible that the condition has become
so severe that voluntary movement no longer has an
effect on symptoms. Counter stimulation such as massa-
ging or hitting the legs can also relieve symptoms.
4. Urge to move or unpleasant sensations are worse in the
evening or at night or occur only in the evening or at night
The circadian pattern of symptoms is necessary for a
diagnosis of RLS to be confirmed. Symptoms are at their
peak in the hours just after midnight and are at their
nadir mid- to late-morning [22,23]. This circadian
rhythm also corresponds to the circadian decreases of
iron availability which may limit dopamine synthesis [24].
Potential barriers to diagnosis
Presentation of symptoms
In general, RLS does not present as a motor-sensitive
problem, but through symptoms such as disturbed sleep
[25], pain or unspecific increased motor activity. The
reason that sleep disturbance is often the reason for
consultation is because the circadian pattern of RLS
causes difficulty in falling asleep, getting back to sleep
[23], and can cause awakenings during the night due to
the discomfort in the limbs [26]. Patients’ quality of life
can also be affected and chronic disruption of sleep or
reduced duration of total sleep time can lead to depres-
sion, anxiety, cognitive and social dysfunction [26-28].
The term “restless legs syndrome”
A major barrier to diagnosing RLS is the language
patients use to describe their symptoms (see Table 2), as
well as cultural differences that appear when RLS suf-
ferers describe these symptoms. For example, a descrip-
tion of symptoms as resembling “water moving in my
legs” does not confer the seriousness and credibility of
symptoms.
RLS is also called Ekbom Syndrome, but the term RLS
has been preferred by the medical community because it
is more descriptive. The problem with the term “restless
legs syndrome” is that it is a term that is confusing,
because it gives the impression that RLS is a lifestyle
disorder as opposed to a nosological entity with a
genetic basis. Genome-wide association studies have
identified gene variants within MEIS1, BTBD9, MAP2K5
and LBOXCOR1 [29]. It lacks the specific relation to a
cause of the symptoms and completely remains in the
descriptive area.
Differential diagnosis and mimics (see table 3)
The diagnosis of RLS necessitates that the physician is
aware of the disorder and its variety of symptoms.
When there is a lack of awareness about what exactly
RLS is, then the probablility of misdiagnosis is more
likely. This is especially the case with RLS mimics,
which meet the essential diagnostic criteria but do not
constitute RLS. Important mimics include peripheral
neuropathy, cramps, positional discomfort, akathisia and
anxiety disorders [30]. RLS also needs to be differen-
tiated from other conditions that can also coexist with it
such as peripheral neuropathy, lower limb pain condi-
tions of different origin, parkinsonism with sensory
Table 2 Common terms use to describe RLS [7]
Creepy-crawly Tearing
Insects/ants crawling Throbbing
Jittery Tight feeling
Pulling Grabbing sensation
Worms moving Itching bones
Soda bubbling in the veins Electric current
Electric current Fidgets
Pain Twitching
Burning Water moving
Tingling Aching
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Meeting Criteria Comment Disorder
Urge to move & unpleasant
sensations in the legs
Symptoms begin/worsen
during periods of rest or
inactivity.
Symptoms relieved with
movement
Symptoms worse in the
evening/night
Definite RLS Awake symptom diagnosis made by clinical history; uncomfortable
urge to move with or without deep creepy-crawling sensation
brought on at time of inactivity or rest (sitting or lying); immediate
relief either complete or partial with movement; symptomatic relief
is persistent as long as movement continues; presence of circadian
pattern with peak around midnight and nadir in the morning
RLS
Urge to move -
Symptoms begin/worsen
during periods of rest or
inactivity.
Symptoms relieved with
movement
Orthostatic hypotension
Neurological
disorder with “urge
to move”
Feeling of restlessness which may be localized in legs, brought on
by sitting still; should not occur while lying down but might be
relieved by movement; occurs in patients with orthostatic
hypotension
Hypotensive akathisia
Unpleasant sensations in
the legs
Symptoms relieved with
movement
Symptoms worse in the
evening/night
No positive response to
dopaminergic drugs
Pain Disorder Dysesthesias and pain in the legs, frequently one-sided, often
radicular arrangement of sensory symptoms, atrophic changes of
musculature, no urge to move the legs, symptoms can be initiated
by sitting and lying and improve by movement, usually neurological
and neurophysiological deficits, does not respond to dopaminergic
therapy
Radiculopathy
Unpleasant sensations in
the legs
Symptoms relieved with
movement
Symptoms worse in the
evening/night -
Vascular Disorder Dysesthesias and pain in the legs. May appear to occur with or after
rest but is associated with or occurs after periods of standing/
walking; ntensity increased by movement and usually relieved by
prolonging rest often best in a lying position, no urge to move, no
circadian pattern, usually no sleep disturbances, frequently
associated with skin alterations and edemas. Often associated with
vascular disease, circadian pattern if any relates more to activity
levels
Vascular claudication,
neurogenic
claudication
Urge to move
Symptoms begin/worsen
during periods of rest or
inactivity
Periodic limb movements
History of neuroleptics
Neurological
disorder with “urge
to move”
Looks like very severe RLS affecting the whole body -but usually
without any sensations of pain reported by RLS patients often no
relief with movement;, should have a history of specific medication
exposure
Neuroleptic-induced
akathisia
Unpleasant sensations in
the legs
Symptoms begin/worsen
during periods of rest or
inactivity
No positive response to
dopaminergic drugs
Pain Disorder Sensory symptoms commonly reported as numbness, burning, and
pain; not as common in RLS; numbness is rare in RLS, no urge to
move; sensory symptoms usually present throughout the day, less
frequent at night, complete and persistent relief is not obtained
while walking or during sustained movement
Neuropathy
No periodic limb
movements
Unpleasant sensations in
the legs
Symptoms begin/worsen
during periods of rest or
inactivity.
Pain Disorder Patients after surgeries frequently do not remember the origin of
their complaints. They almost always report symptoms in the legs or
in the back, when lying or sitting or during movement.
Chronic pain
syndrome (lumbal,
cervical)
Unpleasant sensations in
the legs
Symptoms relieved with
movement
Disorders without
“urge to move”
Often comes on with prolonged sitting or lying in the same
position but usually relieved by a simple change in position, unlike
RLS, which often returns when change of position, movement, or
walking is not continued, no circadian pattern
Positional discomfort
Symptoms relieved with
movement
Symptoms worse in the
evening/night
Neurological
disorder with “urge
to move”
Leg cramps or charley horse cramps can come on at night and are
relieved with stretching or walking; no urge to move; experienced
as a usually painful muscular contraction, often involving the calf
muscles, unlike RLS sensations; sudden onset, occurs not regularly,
short duration, usually palpable contractions
Nocturnal leg cramps
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Ekbom’s description of “irritable legs” underscores that
“the paraesthesia is felt in the lower legs (not the feet).
It is never experienced superficially in the skin, but deep
down in the calf or sometimes the shin) [31]. The high
prevalence of concomitant RLS in the Parkinson’sd i s -
ease population may reflect the medication effect, how-
ever there may also be mimics or overlap of some PD
symptoms with RLS [32,33]. The diagnosis of RLS can
be complicated by a number of other conditions as
shown in Table 3.
Diagnostic algorithm
1. Leading symptoms: Insomnia and unpleasant sensations
in the legs
As with all diagnostic algorithms there has to be a pre-
senting symptom that alerts the physician to the possi-
b l ep r e s e n c eo ft h ed i s o r d e ri nq u e s t i o n .I nr e v i e w i n g
the literature [1,6,34], but also from experience with
patients, the task force concluded that the opening
questions should concern both insomnia or sleep pro-
blems and unpleasant sensations in the legs. Large epi-
demiological studies have demonstrated that the
symptoms with which patients present concern sleep
or unpleasant sensations in the legs. In the REST pri-
mary care study sleep (sleep-related symptoms, day-
time sleepiness) and discomfort in the legs (pain,
twitching and jerks, uncomfortable feelings) accounted
for the most troublesome symptom for majority of
patients [6]. In a general population study more than
75.5% of RLS sufferers report at least one sleep-related
problem [1]. Complaints about sleep problems or leg
problems as a potential indicator for RLS were investi-
gated by Crochard et al.[34]. In this study a diagnosis
of RLS was given to 42.6% of patients with leg com-
plaints, 35.5% of those with sleep complaints, 54.9% of
those with both complaints, and 12.9% of those with
no complaints.
2. The RLS Diagnostic Index (RLS-DI)
If a patient presents with insomnia/sleep problems and
an urge to move, or complains of unpleasant sensations
in the legs, the task force recommends that a series of
questions should be asked. These questions are based
on the RLS-Diagnostic Index (RLS-DI), which is a vali-
dated diagnostic algorithm combining essential and sup-
p o r t i v ed i a g n o s t i cc r i t e r i ao fR L S[ 3 5 ] .T h em o s t
important questions concern the urge to move the legs
and the worsening of symptoms at rest. If a patient
answers yes to three or more of these questions then
the physician should question the patient about asso-
ciated and supportive features (Table 1) of RLS that are
the presence of RLS in the family, a positive response to
dopaminergic therapy, and exclusion of other disorders
(Table 3).
If the patient answers positively to one of the suppor-
tive/associated features, then it is likely that they have
RLS.
The diagnostic algorithm is detailed in Figure 1.
Table 3 Differential diagnosis (Continued)
Unpleasant sensations in
the legs
Symptoms worse in the
evening/night
Sleep disturbance
Sleep-related
Disorders
Involuntary muscle (myoclonic) twitch which occurs during falling
asleep, described as an electric shock or falling sensation which can
cause movements of legs and arms. Occurring once or twice per
night, frequent in the population.
Hypnic jerks
Unpleasant sensations in
the legs
Symptoms worse in the
evening/night
Sleep disturbance
Psychiatric
Disorders
Depressive disorder with somatic symptoms like psychomotor
agitation and diverse somatic complaints, circadian pattern with
early awakening in the morning, daytime sleepiness.
Depression, various
forms with somatic
syndrome
Urge to move
No positive response to
dopaminergic drugs
No sleep disturbance
Neurological
disorder with “urge
to move”
Occurs in subjects who fidget, especially when bored or anxious,
but usually do not experience associated sensory symptoms,
discomfort, or conscious urge to move; symptoms do not bother
the subject, usually lacks a circadian pattern, more of a type of
psychic restlessness, less sleep disturbances, no response to
dopaminergic medication
Volitional movements,
foot tapping, leg
rocking
Urge to move
No positive response to
dopaminergic drugs
No periodic limb
movements
Disorders without
“urge to move”
Discomfort centered more in joints, may not have prominent
circadian pattern as seen in RLS, increase of symptoms during
movement .does not respond to dopaminergics, usually no PLMs
Arthritis, lower limb
Urge to move
Sleep disturbance
Disorders without
“urge to move”
Multiple, alternating, multiform complaints in muscle groups and
joints; sometimes leg-accentuated but mostly whole body affected;
frequent sleep disorders, no circadian pattern, no relief by
movement, no dopaminergic response
Fibromyalgia
Urge to move Vascular Disorder Discomfort in legs, some relief with massage or inactivity Varicose veins
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A chronic disorder requiring long-term treatment
The natural clinical course of RLS varies between pri-
mary (idiopathic) and secondary (symptomatic) forms.
Primary RLS tends to be chronic, with symptom severity
increasing over time, this is especially the case in early-
onset RLS [36], with many patients not developing daily
RLS until the age of 40-60 years [37].
Patients with late-onset RLS often experience a more
rapid progression of symptoms [38]. The remission of
symptoms is possible in primary RLS, although it is dif-
ficult to know the course of RLS in mild or intermittent
A.  Patients with one of the following complaints should be specifically screened for RLS: 
1.  Does the patient complain of insomnia or sleep problems? 
If yes, is it due to a need to move? 
OR 
2.  Does the patient complain of unpleasant (painful) sensations in the legs? 
 
If the patient answered yes to either of the above questions then questions from part B should be put to the patient: 
B.  RLS-Diagnostic Index: [35] [52] 
In the last seven days:  Yes  No 
1. Do you feel an urge to move your legs (arms)?     
2. When feeling an urge to move, do you experience unpleasant sensations in your 
legs (arms) such as tingling, burning, cramps, pain?     
3. Does the urge to move / unpleasant sensations begin or worsen when you are at 
rest (lying, sitting) or when you are inactive?    
4. Does moving partially or completely relieve the urge to move / unpleasant 
sensations (e.g., walking or stretching?)    
5. Does the urge to move / unpleasant sensations increase in the evening or at night 
compared to the day? (That means, complaints are worse at night than during the 
day or occur only in the evening or at night). In severe RLS, this criterion must have 
previously been present. 
  
 
If all are yes then the patient has RLS. If the patient answers yes to at least questions 1 and 3 then proceed to items 6 to 8 
 
Associated and supportive criteria 
  Yes  No 
6. Does a first-degree relative (parents, brothers and sisters, children) suffer from the 
urge to move/ unpleasant sensations (item 1-5)?    
7. Did the urge to move / unpleasant sensations ever improve with dopaminergic 
therapy?     
8. Are you sure that the urge to move / unpleasant sensations cannot be 
satisfactorily explained by other medical factors / concomitant diseases (e.g. muscle 
cramps, positional discomfort, polyneuropathy)? (see table 3) 
  
In addition to positive response to questions 1 & 3 above, if the patient answers yes to one or more questions (6-8) then it is likely that they have RLS.
 
When to refer to a specialist: 
  When the diagnosis remains in doubt 
  No clear-or non-sustained response to dopaminergic therapy 
  Any strictly unilateral leg symptoms 
 
Indications for sleep lab assessment (by a sleep specialist): 
  Daytime sleepiness as the most burdening symptom 
  Differential diagnosis with other sleep disorders (i.e., sleep apnoea or parasomnia) 
  Non-response to dopaminergic therapy 
  Atypical presentation of symptoms 
  Severe symptoms in a young patient (<30 years) 
 
PSG, if available, can help confirm diagnosis, evaluate impact on sleep and exclude other sleep disorders  
 
C.  Clinical evaluation of causes of RLS: 
  Clinical history: 
  Ask about relatives with RLS > RLS is frequently genetic 
  History of iron deficiency > RLS is often caused by iron deficiency: measure ferritin if RLS is suspected 
  Peripheral neuropathy > consider a neurological exam, EMG 
  Pregnancy > RLS is present in approx. 20% of pregnancies 
  Renal disease > 40% of patients have RLS 
  Diabetes > higher prevalence of RLS 
  Drugs that exacerbate RLS (e.g. antidepressants, see table 4) 
 
 
  Laboratory evaluation: 
  Haemoglobin  (exclude  anaemia)     
  Serum creatinine, urea and albumin (exclude renal dysfunction)  
 Serum  glucose     
 Serum  ferritin  (should not be < 50g/L)  
Figure 1 Diagnostic algorithm.
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[39]. It is likely that patients with primary RLS will
require treatment throughout their lives, and therefore
need to be made aware of this before treatment initia-
tion; possible side effects will also need to be discussed
(Table 4). In comparison, secondary RLS might remit
once the underlying condition (pregnancy, iron defi-
ciency, chronic renal insufficiency) is resolved [40-42].
GPs, as well as patients should be made aware that the
differentiation between primary and secondary RLS is
somewhat arbitrary, as in many cases, iron deficiency is
part of primary RLS and may never be completely
resolved although repeatedly treated.
It is important to remember that RLS treatment so far
is symptomatic, not preventive. Treatment improves the
quality of life of the patient and it is therefore important
for the physician to work closely with the patient in tai-
loring treatment to their individual needs and paying
close attention to any symptom fluctuations. In addition,
RLS treatment does not have a constant effect over the
24-hour period, as many RLS treatment options have a
s h o r th a l f - l i f ea n ds h o u l do n l yb ea d m i n i s t e r e daf e w
hours before symptoms begin in the evening. The main
exception to this need is rotigotine, a 24-hr acting drug
that is usually administered as a patch in the morning
and does not need to be adjusted to the individual time
of onset of symptoms (Table 4).
Exacerbators of RLS
Most patients who are diagnosed with RLS will have
already tried and tested many non-pharmacological
options by the time they seek medical attention such as
activities that keep them concentrated, the avoidance of
caffeine and alcohol, hot baths etc, so the task force
decided not to discuss non-pharmacological treatment
in this paper. However, there are a certain number of
medications that are known to exacerbate RLS symp-
toms and their use should be reconsidered, these
include antihistamines, dopamine antagonists, anti-nau-
sea medications, antidepressants, serotonergic reuptake
inhibitors, neuroleptics, beta-blockers, some anticonvul-
sants, and lithium (Table 5) [43].
Drug dosages should be kept to a minimum
The drug dosages given to RLS patients should be kept
to the strict minimum, and the maximum regulatory
dose should never be exceeded (Table 4). It is important
that physicians know that for the dopaminergic agents
the doses required for RLS are far lower than those
used to treat Parkinson’s disease patients. The first-line
treatments for RLS have not been approved in divided
doses (i.e. dividing the full dose into two administra-
tions, to cover evening and sleep, as opposed to dividing
t h ed o s ed u r i n gt h ed a y ) ;w h e n e v e rp o s s i b l ed i v i d i n g
doses should therefore be avoided in as far as that
means increasing the total daily dosage. In some
patients, however, a single dosage may not be sufficient
for long-term treatment and these patients especially
have to be carefully followed to keep the 24 h dosage
low.
Treatment should be administered for a sufficient
duration for an effect on symptoms to be seen before
switching to a different drug. This however, depends on
the individual drug (see Table 4). Caution should be
exercised when increasing the treatment dosage, and
continuous increases should be avoided as this can lead
to a serious treatment-complication called augmentation
(see below).
When to treat?
Clinical significance
RLS should only be treated when it is clinically signifi-
cant, that is, when symptoms impair the patient’s quality
of life, daytime functioning, social functioning or sleep.
To facilitate the evaluation of RLS severity and to moni-
tor treatment efficacy the task force recommends the
Table 4 Overview of treatments
Drug Starting dose and maximum
recommended dosage
Time to full effective
therapeutic dose
Half-
life
Side effects
Levodopa 50 mg
200 mg
At first dose 1.5-2
hours
Augmentation
Rebound
Ropinirole 0.25 mg
4m g
4-10 days 6 hours Nausea, low blood pressure, dizziness, headache, nasal
congestion
Pramipexole 0.125 mg
0.54 mg
At first dose 8-12
hours
Nausea, low blood pressure, dizziness, headache, nasal
congestion
Rotigotine 1-3 mg patches 1 week 5-7
hours
Skin irritation, nausea, low blood pressure, dizziness,
headache, nasal congestion
Pregabalin 25-300 mg 3-6 days 10 hrs Sleepiness, dizziness, headache, fluid retention
Clonazepam 0.50 mg
2.0 mg
First dose: effect mainly on
sleep
30-40
hours
Sleepiness, dizziness, morning drug hangover
Gabapentin 300 mg
2700 mg
3-6 days 5-7
hours
Sleepiness, dizziness, fluid retention
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Page 8 of 13use of a simple sleep diary that should be used for 7-14
days (see Figure 2 also available for download from the
EURLSSG website http://www.eurlssg.org).
How to treat
Categories of treatment and which drugs to use (for
recommended doses see the treatment algorithm Figure 3)
a) Intermittent vs. continuous Patients with RLS are
divided into different treatment categories: intermittent,
daily and refractory.
Clinically significant intermittent RLS is present when
symptoms do not occur frequently enough to require
daily treatment. Although no treatments have been
approved for intermittent RLS, the intermittent use of
levodopa or pramipexole can be considered to be most
appropriate if an off-label treatment is warranted. Other
off-label treatment options include low-potency opioids,
or if symptoms mainly disturb sleep, a hypnotic such as
clonazepam, although its use is off-label. (see Figure 3
for more details).
Daily treatment is necessary for patients with moder-
ate to severe RLS that has a negative impact on their
lives either every day or on most days of the week. In
such cases the dopamine agonists (pramipexole, ropinir-
ole, and rotigotine) are the first-line treatment choice
[8]. If symptoms occur at night, treatment can be
initiated with a low dose of either pramipexole, ropinir-
ole or rotigotine. However, in addition to nighttime
symptoms, the patient might describe symptoms during
the daytime. Such daytime symptoms are not uncom-
mon and can particularly break through during immobi-
lization or any other changes in lifestyle. Such cases
should be treated preferentially with transdermal rotigo-
tine due to its longer duration of action [44]. Second-
line treatment consists of opioid-like drugs (e.g. trama-
dol, tilidine and codeine) but their use over the long-
term could be problematic due to addiction issues [8].
Alpha-2-delta ligands (pregabalin, gabapentin and gaba-
pentin enacarbil) are currently being examined in clini-
cal trials and might constitute a promising alternative if
their efficacy is confirmed in long-term trials [45,46].
Refractory RLS is daily RLS that has been unsuccess-
fully treated with two classes of drugs (one dopaminer-
gic and one non-dopaminergic) at the correct dose and
for an adequate length of time. Refractory RLS should
be referred to the appropriate specialist and no longer
be treated in the primary care clinic.
b) Primary vs. secondary For primary RLS the physi-
cian should administer treatment either intermittently
or continuously as detailed above.
Secondary RLS is often associated with iron deficiency,
low serum ferritin values, pregnancy, end-stage renal
disease (ESRD), rheumatoid arthritis, diabetes or with
neurological disorders such as polyneuropathy, and var-
ious forms of spinal disorders. While laboratory tests
a r el i k e l yt ob en o r m a li np r i m a r yR L S ,i no r d e rt or u l e
out or treat secondary RLS it is important to treat iron
deficiency, which is implicated in both the onset of sec-
ondary RLS as well as in the severity of RLS [47,48], and
is common during pregnancy and ESRD.
The task force recommends that hemoglobin, transfer-
rin saturation and serum ferritin are evaluated in all RLS
patients and that oral iron be administered to replenish
iron when serum ferritin levels are < 50 μg/L. In those
cases, iron substitution should be administered in paral-
lel to other treatments [49]. In some cases, intravenous
iron therapy can be an effective treatment.
Painful forms of RLS or any RLS associated to poly-
neuropathy (diabetes etc.) might respond well to alpha-2
delta agonists (pregabalin, gabapentin). Pramipexole has
also been shown to improve painful symptoms in RLS
patients [50].
For RLS in pregnancy and breast-feeding, only iron
and folic acid can be recommended. There are no speci-
fic recommendations for the elderly (> 75 yrs). Children
with RLS should be referred to an RLS expert.
c) Daytime symptoms? RLS symptoms can occur dur-
ing the day, and at least in one study, this has shown to
occur in over 40% of the cases [6]. In such cases the
task force recommends treatment with rotigotine, which
is administered as a patch and provides therapeutic
plasma levels over the entire 24-hr period. Extended
release dopamine agonists are available for other
Table 5 Drugs that may exacerbate RLS
Diphenhydramine (and other over the counter cold remedies)
Metoclopramide
Prochlorperazine
Chlordiazepoxide
Traditional antipsychotics (phenothiazines)
Atypical neuroleptics (olanzapine and risperidone)
Antidepressants (especially norepinehrine or selective serotonin
reuptake inhibitors)
Anticonvulsants (zonisamide, phenytoin, methsuximide)
Antihistamines
Opiods
Figure 2 Symptom diary.
Garcia-Borreguero et al. BMC Neurology 2011, 11:28
http://www.biomedcentral.com/1471-2377/11/28
Page 9 of 13indications but have not been approved for RLS. So far,
no studies have been published on their use and poten-
tial advantages over standard immediate release forms
in RLS.
2. How long to treat
Unfortunately, at the present time, data are lacking con-
cerning treatment duration. However, the task force
recommends that treatment should be stopped in the
following cases:
￿ On the patient’s request;
￿ Following causal interventions (e.g. renal
transplants);
￿ Periodically, e.g., every year for a few days if possi-
ble, to evaluate whether there are any spontaneous
fluctuations in disease severity. This is not applicable
Figure 3 Treatment algorithm.
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affected
3. Treatment follow-up
Despite the existence of RLS severity rating scales,
which are used in clinical trials, the task force agreed
that such scales should not be used to initiate treatment.
Although severity has been shown to correlate suffi-
ciently with the patient’s quality of life, this may depend
upon the scale rather than the true clinical picture.
Principally, the task forcer e c o m m e n d st h a tt h eG P
should see the RLS patient every six to twelve months
for follow-up. In order to appropriately monitor treat-
ment efficacy and non-responders, the use of a simple
symptom diary is recommended (Figure 2). This diary
will give an indication of the severity of the patient’s
symptoms and the effect of treatment, and will also
enable the identification of augmentation.
Treatment complications
When to refer to a specialist?
Patients should be referred to a specialist (either a sleep
specialist or a neurologist) if treatment proves to be
unsuccessful. The task force defines unsuccessful treat-
ment as:
￿ an insufficient initial response despite an adequate
dose and duration of treatment;
￿ t h er e s p o n s et ot r e a t m e n tbecomes insufficient
after a time despite an increased dose;
￿ there are intolerable side effects;
￿ the patient reaches the maximum recommended
dosage and treatment ceases to be effective;
￿ augmentation develops;
￿ In general, children should not be treated at the
primary care level.
Augmentation
Augmentation is the main complication of long-term
dopaminergic treatment of RLS. It is characterized by an
overall increase in RLS symptom severity which means
that the symptoms appear earlier in the day, they occur
quicker when the patient is at rest, and may spread to
other body parts including the trunk and arms. The
most effective way of preventing augmentation is to
keep the dose of the dopaminergic medication as low as
possible, ensuring that it does not exceed the dose
recommended by regulatory authorities, and to prefer
drugs with a long half-life/duration of action (see
above). If augmentation is suspected then treatment
should be changed from a dopaminergic to either a
longer-acting dopaminergic or to a non-dopaminergic
drug [51], except in the case of augmentation under
levodopa when a switch to a dopamine agonist is
recommended in the first instance. If this proves to be
unsuccessful, referral to a specialist is recommended.
When should augmentation be suspected?
Augmentation should be considered a possibility when
￿ any maintained increase in symptom severity
despite appropriate treatment;
￿ any maintained increase in symptom severity fol-
l o w i n gad o s ei n c r e a s e ,p a r t i c u l a r l yi fad o s er e d u c -
tion leads to an improvement in symptoms;
￿ any earlier onset of symptoms in the afternoon/
evening;
￿ any spreading of symptoms to previously unaf-
fected body parts;
￿ any shorter latency to symptom onset during the
day when at rest.
Discussion and Conclusion
RLS is a common condition that can present frequently
in primary care setting. Due to the important conse-
quences on quality of life, and the availability of treat-
ment, it is important to identify such cases in primary
care. RLS is probably one of the most easily manageable
medical causes of insomnia, and thus, it is important
that GPs become familiar with this disorder, it’sd i a g n o -
sis and management. Given the impact of RLS on qual-
ity of life and the marked therapeutic efficacy of current
treatments in improving these symptoms, its early iden-
tification and treatment is highly relevant.
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